Physician profile
Julia Beiter
NPI 1952181158
$5,708.81
in general payments reported to CMS, 2019-2025
20 companies · $3,396 in 2025
The $3,396 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $2,211 · 2025: $3,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,306 · Consulting Fee: $1,350 · Education: $52.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,306.36 |
| Consulting Fee | $1,350.00 |
| Education | $52.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,116.84 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,441.06 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $676.60 | 2023-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $431.54 | 2024-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $324.37 | 2024-2025 | Voquezna |
| Genzyme Corporation | $140.62 | 2023-2025 | |
| Evoke Pharma, INC. | $128.83 | 2025 | |
| Celltrion USA INC. | $70.05 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $64.15 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.94 | 2024-2025 | Xifaxan, Trulance |
| Vivus LLC | $39.98 | 2024 | Qsymia |
| Qol Medical, LLC | $34.63 | 2024 | Sucraid |
| Pfizer INC. | $31.43 | 2024 | |
| Celgene Corporation | $28.58 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $26.14 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $20.98 | 2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $19.80 | 2024 | Dificid |
| Lilly USA, LLC | $18.30 | 2024 | Omvoh |
| Ardelyx, INC. | $16.38 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $14.59 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Beiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.